Skip to main content

Table 1 Demographic, clinical, and laboratory features of systemic sclerosis patients and controls

From: Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study

  Systemic sclerosis patients
(n = 50)
Healthy controls
(n = 38)
Female gender (%) 47 (94.0) a 36 (94.7) a
Age (years) 57.2 ± 12.8 b 55.2 ± 11.4 b
European-derived (%) 40 (80) 24 (68.6)
Smoking status (%)
 Never 25 (50) 23 (65.7)
 Previous 21 (42) 30 (29.7)
 Current 4 (8) 2 (5.7)
Disease duration (years) 15 (7–21)  
Diffuse cutaneous involvement (%) 14 (28.0)  
Modified Rodnan skin score 6 (2.8–10.3)  
Renal crisis 4 (8.0)  
Gastrointestinal symptoms (%)
 Heartburn 25 (50.0)  
 Dysphagia 26 (52.0)  
 Diarrhea / constipation 21 (42.0)  
DLCO (% predicted) 70.1 ± 16.3  
 Reduced DLCO (< 80% predicted) 52.9 (15.9)  
FVC (% predicted) 79.2 ± 18.9  
 Reduced FVC (< 80% of predicted) 22 (44)  
PASP 31.7 ± 14.4  
 Pulmonary hypertension (PASP ≥40 mmHg) (%) 5 (10)  
Autoantibodies (%)
 ANA 39/50 (78.0)  
 Anti-Ro/SSA 1/45 (2.2)  
 Anti-La/SSB 0/45 (0)  
 Anti-Scl-70 4/44 (9.1)  
 RF 35/50 (75.0)  
Medications (%)
 Prednisolone < 20 mg/day 6 (12)  
 Mycophenolate mofetil 4 (8)  
 Previous methotrexate administration 10 (20)  
 Previous rituximab administration 2 (4)  
 Previous cyclophosphamide administration 12 (24)  
  1. Data are shown as mean (± standard deviation), median (interquartile ranges) or number (n)
  2. ANA anti-nuclear antibodies, Anti-dsDNA anti-double-stranded DNA, Anti-Scl70 antitopoisomeraseI, DLCO diffusion capacity of carbon monoxide, FVC forced vital capacity, PASP arterial systolic pressure on Doppler echocardiography, RF rheumatoid factor, SSc systemic sclerosis
  3. a Mann-Whitney test, p = 1.000
  4. b Student’s T test, p = 0.448